Stockreport

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant, Inc.  (IMVT) 
PDF Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batocl [Read more]